Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Iksuda Therapeutics
Iksuda Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
LegoChem and Iksuda expand ADC license agreement
In April 2020, Iksuda licensed global development and commercialisation rights for three ADC programmes using LCB's ADC linker/toxin platform
Finance
ADC developer Iksuda Therapeutics closes $47m financing round
The company’s lead preclinical candidate, IKS03, is a CD19-targeted ADC candidate for B-cell cancers
Research & Development
Iksuda releases first data on ADC efficacy on tumour regression
British next-gen Antibody Drug Conjugates developer says its IKS01 allows for the targeted delivery of a potent cytotoxic payload to tumours
Pharmaceutical
Iksuda and Femtogenix ink solid tumour agreement
Iksuda has stated it will use Femtogenix payload molecules to progress its lead antibody drug conjugate
Media
Glythera announces corporate name change and rebranding
Now the primary focus of Iksuda Therapeutics will be on the development of superior ADCs for treatment of difficult-to-treat cancers
Ingredients
Glythera appoints Professor Kerry Chester to SAB
Recruitment
Glythera appoints Chief Scientific Officer and strengthens SAB
Subscribe now